You just read:

Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jul 17, 2018, 17:31 ET